• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast®
  • Blog
  • BioBlast®
  • Contact Us

Pharma Intelligence announces Global Generics & Biosimilars Digital Awards Winners

by Naomi Pearce, Emily Bristow | Nov 5, 2020 | Uncategorized

Pharma Intelligence announced the Global Generics & Biosimilars Digital Awards Winners. Alvogen, Accord Healthcare, Aurobindo, STADA, Dr Reddy’s Laboratories, Samsung Bioepis, and Richard Saynor of Sandoz were among the winners.

American Academy of Managed Care Pharmacy eLearning Days discuss biosimilar launches in US

by Bioblast Editor | Apr 23, 2020 | Other Updates, Uncategorized

On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in...

Centre for Biosimilars reports biosimilar bills introduced to US Congress

by Naomi Pearce, Emily Bristow | Mar 19, 2020 | Uncategorized

On 19 March 2020, the Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US Congress in the 2 weeks prior. These bills include a ‘shared savings’ model designed to encourage physicians to switch patients to...

Pfizer announces hestitance to launch Amsparity in EU

by Naomi Pearce, Emily Bristow | Feb 28, 2020 | Uncategorized

Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity (adalimumab) in the EU, citing unfavourable market conditions.

Harbour BioMed receives FDA approval of Investigational New Drug application

by Naomi Pearce, Emily Bristow | Feb 28, 2020 | Uncategorized

On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.

BioPharma Reporter reports AbbVie defence strategy for Humira

by Naomi Pearce, Emily Bristow | Feb 18, 2020 | Uncategorized

On 18 Feb 2020, BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab) competition in the US market. According to the BioPharma Reporter, AbbVIe CEO Gonzalez that explained AbbVie’s commercial US strategy will mimic the...

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast® via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast®
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast®

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?